FDA Inspection 1152174 — Takeda Pharmaceuticals U.S.A.
The FDA completed an inspection of Takeda Pharmaceuticals U.S.A. on September 1, 2021 in Lexington, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 1, 2021
- Fiscal Year
- 2021
- Product Type
- Biologics
- Project Area
- Bioresearch Monitoring
- Location
- Lexington, MA (United States)
Additional Details
Sponsor, Contract Research Organization